[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA51297B1 - Quinazolinones as parp14 inhibitors - Google Patents

Quinazolinones as parp14 inhibitors

Info

Publication number
MA51297B1
MA51297B1 MA51297A MA51297A MA51297B1 MA 51297 B1 MA51297 B1 MA 51297B1 MA 51297 A MA51297 A MA 51297A MA 51297 A MA51297 A MA 51297A MA 51297 B1 MA51297 B1 MA 51297B1
Authority
MA
Morocco
Prior art keywords
quinazolinones
parp14
inhibitors
parp14 inhibitors
cancer
Prior art date
Application number
MA51297A
Other languages
French (fr)
Other versions
MA51297A (en
Inventor
Kevin Wayne Kuntz
Laurie B Schenkel
Melissa Marie Vasbinder
Kerren Kalai Swinger
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Priority claimed from PCT/US2018/066700 external-priority patent/WO2019126443A1/en
Publication of MA51297A publication Critical patent/MA51297A/en
Publication of MA51297B1 publication Critical patent/MA51297B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des quinazolinones et des composés apparentés qui sont des inhibiteurs de parp14 et sont utiles, par exemple, dans le traitement du cancer et de maladies inflammatoires.The present invention relates to quinazolinones and related compounds which are inhibitors of parp14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

MA51297A 2017-12-21 2018-12-20 Quinazolinones as parp14 inhibitors MA51297B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608747P 2017-12-21 2017-12-21
PCT/US2018/066700 WO2019126443A1 (en) 2017-12-21 2018-12-20 Quinazolinones as parp14 inhibitors

Publications (2)

Publication Number Publication Date
MA51297A MA51297A (en) 2020-10-28
MA51297B1 true MA51297B1 (en) 2023-01-31

Family

ID=71842911

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51297A MA51297B1 (en) 2017-12-21 2018-12-20 Quinazolinones as parp14 inhibitors

Country Status (2)

Country Link
AR (1) AR114003A1 (en)
MA (1) MA51297B1 (en)

Also Published As

Publication number Publication date
MA51297A (en) 2020-10-28
AR114003A1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
MA45029A (en) ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA202091709A1 (en) DNA PC INHIBITORS
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
AR119389A1 (en) INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES
MA39193B1 (en) Gpr6 modulators based on tetrahydropyridopyrazines
MA43335B1 (en) Transthyretin (ttr) arni compositions and methods for use thereof for the treatment or prevention of diseases associated with ttr
MA41060B1 (en) Compositions comprising bacterial strains
MA55434B1 (en) Compositions comprising bacterial strains
MA41010B1 (en) Compositions comprising bacterial strains
MX2020006365A (en) Quinazolinones as parp14 inhibitors.
MA40132A1 (en) Macrocyclic Inhibitors of Protein / protein Interactions pd-1 / pd-11 and cd80 (b7-1) / pd-li
EA202091708A1 (en) DNA PC INHIBITORS
EA201891468A1 (en) COMPOSITIONS AND METHODS TO REDUCE TAU EXPRESSION
MA47736B1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
EA201892714A1 (en) IMIDAZOLINE CONNECTIONS AS ELASTASY HUMAN NEUTROPHIL INHIBITORS
EA201791937A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES
MA52920B1 (en) Compositions and methods relating to pyridinoylpiperidine 5-ht1f agonists
MA51297B1 (en) Quinazolinones as parp14 inhibitors
EA202090944A1 (en) ANTI-CD3-ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING ONCOLOGICAL DISEASES, CONTAINING IT
EA202091524A1 (en) INHIBITORS OF THE PROTEASE 2 ACTIVATED RECEPTOR
EA202091542A1 (en) QUINAZOLINONES AS PARP14 INHIBITORS
EA201990393A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 USED FOR TREATING VARIOUS DISEASES AND DISORDERS
EA201991735A1 (en) AZOLOPYRIMIDINES FOR TREATMENT OF CANCER DISEASES
EA202092082A1 (en) AMINOPYRAZINDIOL COMPOUNDS AS PI3K INHIBITORS